|
Best model reduction approach for Fine-Gray prediction model
|
|
5
|
75
|
March 27, 2026
|
|
Scoping review + SOCI: to assess DHIS2 applicability for NCD
|
|
2
|
57
|
March 26, 2026
|
|
FDA Draft Guidance: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
|
|
10
|
760
|
March 2, 2026
|
|
One-sided significance threshold of less than 0.1 in Phase 2 clinical trial
|
|
7
|
122
|
February 25, 2026
|
|
Statin-related side effects: the recent Lancet publication is biased toward false-negatives
|
|
19
|
479
|
February 19, 2026
|
|
Bootstrapped variable selection in the presence of competing risk
|
|
7
|
129
|
January 12, 2026
|
|
The growing interest in integrating causal inference and Design Theory
|
|
7
|
237
|
January 6, 2026
|
|
Should causal modeling be a required part of a NIH grant applications?
|
|
1
|
113
|
December 17, 2025
|
|
Randomized non-comparative trials: an oxymoron?
|
|
73
|
4499
|
December 15, 2025
|
|
Cause-Agnostic RCT (CAR)
|
|
9
|
461
|
December 12, 2025
|
|
A High-Fiber Plant-Based Diet in Myeloma Precursor Disorders – Results from the 2 NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
|
|
2
|
97
|
December 11, 2025
|
|
MICE Imputation Models
|
|
10
|
432
|
December 6, 2025
|
|
NEJM Trial - proportional hazard assumption
|
|
12
|
392
|
December 1, 2025
|
|
The Design Theory /Causal Inference Divide Explained by the Position of U
|
|
2
|
149
|
November 28, 2025
|
|
Rarity Roulette: A simulator for estimating hypothetical outcomes spreads for mass screenings
|
|
2
|
95
|
November 20, 2025
|
|
Individual response
|
|
266
|
49097
|
November 17, 2025
|
|
When and why (not) to worry about the PO assumption
|
|
4
|
670
|
October 9, 2025
|
|
Comparing multiple groups to a reference group
|
|
7
|
231
|
October 6, 2025
|
|
Bayesian Clinical Trials: Interview with Frank Harrell
|
|
0
|
238
|
September 18, 2025
|
|
Estimating the probability of neonatal sepsis with plug-in incidence
|
|
6
|
142
|
September 11, 2025
|
|
Fine-Gray vs Cause-Specific Cox Regression
|
|
0
|
151
|
September 11, 2025
|
|
Sample Size Calculation for a 2x2 Factorial RCT
|
|
6
|
356
|
September 3, 2025
|
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
32
|
4257
|
August 12, 2025
|
|
Illogic of Weighting While Estimating Model Parameters
|
|
13
|
828
|
August 11, 2025
|
|
Statistical Process Control and Experimental Design
|
|
9
|
428
|
May 13, 2025
|
|
Challenges in determining meaningful between group differences of surgery vs non-surgical treatment
|
|
12
|
788
|
May 9, 2025
|
|
Why the Non-Reproducibility of Acute Care RCT? The CAP studies
|
|
6
|
207
|
May 8, 2025
|
|
Should I Exclude Patients Based on Treatment Criteria?
|
|
4
|
92
|
April 29, 2025
|
|
Reanalyzing MERIT design using Julia + recent numerical algorithms
|
|
2
|
186
|
April 28, 2025
|
|
Decision analysis calculations
|
|
17
|
482
|
April 27, 2025
|